0EVI Stock Overview
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0EVI from our risk checks.
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.16 |
| 52 Week High | €3.26 |
| 52 Week Low | €2.12 |
| Beta | 0.67 |
| 1 Month Change | -0.35% |
| 3 Month Change | -14.09% |
| 1 Year Change | -18.92% |
| 3 Year Change | -37.25% |
| 5 Year Change | -63.12% |
| Change since IPO | 6.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0EVI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.6% | -1.9% | -0.9% |
| 1Y | -18.9% | -30.5% | -1.8% |
Return vs Industry: 0EVI exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0EVI underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0EVI volatility | |
|---|---|
| 0EVI Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0EVI has not had significant price volatility in the past 3 months.
Volatility Over Time: 0EVI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 179 | Herve Brailly | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| 0EVI fundamental statistics | |
|---|---|
| Market cap | €175.02m |
| Earnings (TTM) | -€7.57m |
| Revenue (TTM) | €61.64m |
2.8x
P/S Ratio-23.1x
P/E RatioIs 0EVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0EVI income statement (TTM) | |
|---|---|
| Revenue | €61.64m |
| Cost of Revenue | €56.02m |
| Gross Profit | €5.62m |
| Other Expenses | €13.19m |
| Earnings | -€7.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 12, 2024
| Earnings per share (EPS) | -0.094 |
| Gross Margin | 9.12% |
| Net Profit Margin | -12.28% |
| Debt/Equity Ratio | 75.3% |
How did 0EVI perform over the long term?
See historical performance and comparison